Mental Health

Zuranolone is a rapid-acting, once-daily, 14-day oral short course therapy for adult patients with major depressive disorder and postpartum depression.

Data show that despite declines in visit rates to federally qualified health centers, patients with psychological disorder diagnoses during COVID-19 did well when telemedicine was available.

Commonly known as “relationship addiction,” co-dependency involves emotional, spiritual, physical, or mental enmeshment with a loved one.

Patient selection is a key factor in the safe and effective administration of advanced pain management modalities.

Adults with attachment anxiety were more likely to misremember facts when they could see the person speaking.

Comedy has taught me several keys that have helped alleviate and manage burnout.

Students can begin learning about treating patients with trauma early.

Study finds early career workers were more likely to disengage during the pandemic, such as by showing a lack of interest or becoming cynical about work.

The objective of the study was to estimate recent trends in cigarette use and health insurance coverage for US adults with and without mental health and SUD.

Demand for treatment of anxiety and depression remained high for the third consecutive year as the demand for the treatment of trauma- and stressor-related and substance use disorders has increased.

Anxiety disorders include generalized anxiety, social anxiety, panic disorder, and fear of certain places or situations, including crowds and public transportation.

Analysis indicates that a 25-mg dose reduces the condition scores significantly more than a 1mg dose over a 3-week period, but the 10-mg dose did not yield the same results.

Providing trauma-informed care is a crucial role for pharmacists.

With many different classes of medications used in the treatment of major depressive disorder, pharmacists can have a significant impact on patients' lives, from counseling on medications to assisting with finding the right medication.

Systemically administered hormonal therapy may be associated with a greater risk of depression before and during menopause.

People with anxiety and related disorders were found to have vaccine hesitancy related to concerns regarding adverse effects and efficacy.

The benefits of psychedelic medicine could expand into long-lasting and transformative therapeutics to treat depression better than selective serotonin reuptake inhibitors (SSRIs).

New research suggests that ketamine can help rehabilitate those who suffer from an eating disorder, and it is important to recognize the root cause of this mental health crisis.

Experts discuss the clinical and economic impact of misdiagnosing bipolar I disorder as major depressive disorder.

New research finds that mental health has replaced COVID-19 as the top health concern among Americans, but deeper analysis needs to be done into whether depression and anxiety are truly becoming more widespread.

Male students admitted into a high-performing public charter school found to have better physical health and lower body mass index than their female counterparts.

New research suggests that MDMA may offer promising benefits to patients with certain unmet psychological treatment needs.

New research suggests that psychedelics, and specifically ketamine, can increase neuroplasticity to help a patient with an eating disorder get “unstuck,” and help treat the disorder better than psychotherapy alone.

Pharmacists play an important role in the recovery journey for patients who decide medication assisted treatment is right for them.

The research further supports zuranolone as a potential episodic treatment for people with MDD, according to the study authors.

Pharmacists dispensing Lybalvi should understand that potentially life-threatening consequences can occur if opioids are taken concurrently.

Following the success of the phase 3 EMERGENT-2 trial, researchers suggest that xanomeline-trospium could be a safe and effective treatment option for adults with schizophrenia.

Many drugs for these conditions enter clinical trials, but few demonstrate success.

Using your voice as a health care professional and supporting each other through burnout are just a few ways to better advocate in the profession.

The New Drug Application for aripiprazole 2-month, ready-to-use, long-acting injectable could lead to the first FDA approval of a 2-month schizophrenia and bipolar I disorder antipsychotic treatment.